Yesterday I started looking into some Mark Skousen-teased ideas for ways to profit when the Chinese bubble bursts — today, as promised, we’ll steer the Thinkolator further along this same path and see if we can identify the other ideas he pitched. If you missed part one of our journey, you can see it here. [...]
Today’s teasers come in from Mark Skousen, who edits the Forecasts & Strategies newsletter and has graced our pages a few times in the past — most recently when he touted Cubist Pharmaceuticals very aggressively as a “winning lottery ticket” and “superbug killer” (that one did quite well, thanks to both the FDA and a [...]
Mark Skousen, who is one of those Ph.D-type doctors (economics) and thankfully doesn’t always insist on being called Dr. Skousen (yes, we’re looking at you Dr. Leeb), is pitching a health care stock today as a teaser for his Forecasts and Strategies newsletter. And like some folks we’ve heard from in the past, he’s teasing [...]
I don’t write about Mark Skousen all that often, in part because he doesn’t regularly barrage us with detailed stock teasers … but I’ve had a lot of readers write in to ask me about this latest teaser ad for his Forecasts and Strategies newsletter, an ad in which he says his favorite stock kept [...]
On this bright and sunny Spring day our thoughts turn … to Mark Skousen. He’s selling subscriptions to his Forecasts & Strategies newsletter, and his pitch is that he predicted the 1980s boom, and warned investors that corporate profits were peaking in early 2007 … and that he’s got the best ideas for you to [...]
It’s been quite a while since I looked at anything by Mark Skousen, but I had quite a number of queries about this teaser ad last week … and I confess, it piqued my interest a bit, too. So what is his “Comeback Stock of 2010?” Well, he’d be happy to tell you, of course [...]
I haven’t written much about Mark Skousen in recent months — at least partly because he hasn’t been using teaser emails very aggressively, or at least not ads that tease specific picks of his that he thinks will soar. So I’m delighted to see that he’s returned to tease us again — this time, he’s [...]
I mentioned that I wanted to get to this one today — it’s probably not in time for most of you to catch it in the Monday email alert, but here it is anyway. Mark Skousen is touting a bank stock for his Forecasts and Strategies newsletter, and more specifically he’s predicting that the bank [...]
Taking a brief break from dissecting Ann Sosnowski’s latest 13F teasers, we move along to look at one that just started cropping up in my inbox from Mark Skousen and his Forecasts and Strategies newsletter. I’ve looked at lots of Skousen’s teasers before — he has picked some good ones like China Medical, which he [...]
Many of you saw this email last week, the latest in a long string of Mark Skousen’s attempts to predict breakout stock performance on earnings dates. His past history of this is spotty, and I’ve written a few times about earnings pops he has predicted — some good, some bad. Alas, I didn’t get a [...]
I’ve written about various teasers from Mark Skousen’s services several times over the last year or so, and he is, at least, always confident. He has teased several good stocks that have performed well, including Sadia, ABB, and CVRD, and several that have stunk — like Volcano and Centerline Holdings (to be fair, I thought [...]
“Last week everything was going down the drain, and now everything’s perfect” — that’s a comment I heard on CNBC this morning, facetious though it was, that goes a long way toward mirroring the movement in gold prices. Last week armageddon was coming and everyone wanted to own gold, today maybe the world financial system [...]
This one came in from a few readers via email today, which is always delightful — but today it was even more of a delight, because here we have a company whose shares I own, and whose future I’m also fairly excited about. The ad is for Mark Skousen’s Hedge Fund Trader service, one of [...]
Ah, it’s so nice to have a lovely little sleuthing job to distract me … this is much more enjoyable than watching my own portfolio tick lower, or watching the market indexes crawl frantically into into the basement like scared children in a horror movie. Enough distractions like this, and I can actually follow through [...]
This one opens up with some tantalizing language, of course: “NEW GOVERNMENT POLICY PROMISES TO FLOOD NEW PROFITS INTO THIS HIGH-DIVIDEND PAYING COMPANY!” It’s from Mark Skousen, from his High Income Alert newsletter — and of course, if you’d please subscribe, he’ll tell you the name of this secret telecom stock that’s paying massive dividends [...]
This email came in today from Mark Skousen, and since it’s a quick and dirty one I thought I’d throw it into the mix for y’all. Skousen’s Hedge Fund Trader, which is what’s being advertised here, is predicting that this Brazilian company will report earnings on October 25 and blow the market away. Now, before [...]
This one comes in from Mark Skousen, who we hear teasing new ideas with some regularity, but this particular ad is for his high-income alert, which I haven’t seem an ad for prior to now. I have heard him talking quite a bit about dividends of late, whenever he gives a talk or is quoted [...]
Here we have another email ad for the Skousen Hedge Fund Trader, which has steered us toward both good and bad ideas lately (at least, good or bad if we’re looking at short term performance — which isn’t necessarily what Skousen is aiming for). This one sounds pretty appealing when we have markets moving like [...]
This one was sent in by a reader, along with a suggestion for the solution (which, as so often with the Gumshoe’s readers, appears to be correct). It’s from Mark Skousen in the form of an ad for Forecasts and Strategies, and, as you have guessed from the title of this note, it’s about a [...]
Here’s one that was sent in by a reader a little while ago — it’s for Mark Skousen’s Forecasts & Strategies, which we’ve seen before a few times (the last pick we sleuthed out, China Medical, did pretty well for him). And this is another medical technology stock, so perhaps it warrants some attention. The [...]
